Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery

Hepatology

Volumn 46, Issue 1, 2007, Pages 84-94

  Wen, Wei Hong ^a   Liu, Jia Yun ^a   Qin, Wei Jun ^a   Zhao, Jing ^a   Wang, Tao ^a   Jia, Lin Tao ^a   Meng, Yan Ling ^a   Gao, Hui ^a   Xue, Cai Fang ^a   Jin, Bo Quan ^a   Yao, Li Bo ^a   Chen, Si Yi ^b   Yang, An Gang ^a,c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; FLUORESCEIN ISOTHIOCYANATE; HEPATITIS B SURFACE ANTIGEN; HYBRID PROTEIN; PROTAMINE; SMALL INTERFERING RNA;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE REPLICATION; HEPATITIS B; HEPATITIS B VIRUS; IN VIVO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; PLASMIDS; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 34547403273     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21663     Document Type: Article

References (38)

1. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-747.
2. Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001;2:110-119.
3. Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. HEPATOLOGY 2003;37:764-770.
4. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication, HEPATOLOGY 2005;41:1349-1356.
5. Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. HEPATOLOGY 2003;38:842-850.
6. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003;21:639-644.
7. Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A 2005;102:773-778.
8. Radhakrishnan SK, Layden TJ, Gartel AL. RNA interference as a new strategy against viral hepatitis. Virology 2004;323:173-181.
9. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-1007.
10. Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005;12:5-11.
11. Dykxhoorn DM, Lieberman J. The silent Revolution: RNA interference as basic biology, research tool and therapeutic. Annu Rev Med 2005;56:401-423.
12. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005;107:222-239.
13. Chiu SJ, Ueno NT, Lee RJ. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 2004;97:357-369.
14. Guillem VM, Tormo M, Revert F, Benet I, Garcia-Conde J, Crespo A, et al. Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines. J Gene Med 2002;4:170-182.
15. Li S, Tan Y, Viroonchatapan E, Pitt BR, Huang L. Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. Am J Physiol Lung Cell Mol Physiol 2000;278:L504-L511.
16. Chen SY, Zani C, Khouri Y, Marasco WA. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther 1995;2:116-123.
17. Li X, Stuckert P, Bosch I, Marks JD, Marasco WA. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther 2001;8:555-565.
18. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-717.
19. Vornlocher HP. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol Med 2006;12:1-3.
20. Wen WH, Zhao J, Yu CJ, Xu YM, Jin M, Wang CJ, et al. Construction of single-chain Fv gene of anti-HBsAg and its expression in COS-7 cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2003;19;163-167.
21. Wen WH, Qin WJ, Gao H, Zhao J, Jia LT, Liao QH, et al. An HBsAg specific scFv derived from a natural immune Fab phage display library is specifically internalized by HepG2.2.15 cells. J Viral Hepat 2006. DOI: 10.1111/j.1365-2893. 2007.00843.x.
22. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985;230:1157-1160.
23. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-553.
24. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004;22:326-330.
25. Taylor P, Pickard G, Gammie A, Atkins M. Comparison of the ADVIA Centaur and Abbott AxSYM immunoassay systems for a routine diagnostic virology laboratory, J Clin Virol 2004;30:S11-S15.
26. Chen Y, Du D, Wu J, Chan CP, Tan Y, Kung HF, et al. Inhibition of hepatitis B virus replication by stably expressed shRNA. Biochem Biophys Res Commun 2003;311:398-404.
27. Guo S, Tschammer N, Mohammed S, Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther 2005;16:1097-1109.
28. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, et al. Cancer siRNA therapy by tumot selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149.
29. Williams BR. Targeting specific cell types with silencing RNA. N Engl J Med 2005;353:1410-1411.
30. Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006;17:117-124.
31. Kojima T. Immune electron microscopic study of hepatitis B virus associated antigens in hepatocytes. Gastroenterol Jpn 1982;17:559-575.
32. Onishi S, Saibara T, Ito K. Hepatitis B surface antigen specific cytotoxic T lymphocyte activity in hepatitis B virus infection. Gastroenterol Jpn 1985;20:330-337.
33. Chu CM, Liaw YF. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection: hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 1987;92:220-225.
34. Sasaki H, Kojima T, Matsui S, Aoyama K, Inoue K. Interaction of lymphocytes with hepatocytes containing hepatitis B antigen: ultrastructural demonstration of target antigen and T-cell subsets by the peroxidase antibody technique. Virchows Arch A Pathol Anat Histopathol 1987;411:489-498.
35. Simon K, Lingappa VR, Ganem D. Secreted hepatitis B surface antigen polypeptides are derived from a transmembrane precursor. J Cell Biol 1988;107:2163-2168.
36. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005;54:117-142.
37. Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, Leake D, et al. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 2006;12:988-93.
38. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005;348:1079-1090.